Oceania Healthcare's (NZE:OCA, ASX:OCA) progress in care suits holds potential for near-term upside in free cash flow growth and re-rating, Jarden Research said in a Nov.25 note.
The healthcare services provider reported a loss of NZ$0.024 per share for the six months ended Sept. 30, compared with earnings of NZ$0.049 per share a year earlier.
Loss for the period was NZ$17.1 million, reversing the NZ$35.2 million profit a year earlier.
Jarden believes that Oceania Healthcare's faster realization of deferred management fees for care suites provides potential for nearer-term upside in free cash flow growth.
Faster realization of the fees, progress on further development execution, and inventory sell-down "could re-rate OCA sooner, taking into account other factors," Jarden added.
The investment firm maintained the company's neutral rating but raised its price target to NZ$0.83 from NZ$0.80.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。